On Target for 400m Tonnes of Decarbonisation - Carbon13 Closes Successful Seed Round of Over $2.2m
20.7.2023 09:33:00 EEST | Business Wire | Press release
Carbon13, the venture builder for the climate emergency, is today announcing the close of its latest seed round, resulting in over $2.2m.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230719330116/en/
L-R, Jonathan Cumming, Chief Financial Officer & Managing Director, Dr Chris Coleridge, Founder & CEO, Dr Nicky Dee, Co-founder & Chief Sustainability and Innovation Officer, Michael Langguth, Co-founder & Chief Strategy Officer (Photo: Business Wire)
The new funding is set to boost Carbon13’s operations significantly and propel Carbon13’s current and future ventures towards the key target of 400 million tonnes of decarbonisation.
The successful funding round was made possible thanks to a range of family offices and venture firms, including True Ventures, a Silicon Valley-based venture capital firm focused on early stage technology startups.
The new injection of funding for Carbon13 will enable a significant increase in climate startup production and a scaling of ambition. Currently, Carbon13 ventures possess an annual mitigation potential of over 420 million tonnes of CO2e – this potential is now set to rise further, as is the number of invested ventures built through Carbon13 programmes since 2021 (currently 46).
In addition, since 2021, Carbon13 has now supported over 350 startup founders through its three programmes (Venture Builder Europe, Venture Builder UK, and Venture Launchpad). This number is also set to grow significantly thanks to the new funding. By end of 2025, Carbon13's Venture Builder is on course to support over 1,000 entrepreneurs to build at least 200 startups.
Commenting on the successful funding round, CEO and Founder of Carbon13, Chris Coleridge, said: “This investment from True Ventures and four family offices is crucial to Carbon13’s plans for scaling our support to entrepreneurs tackling the most urgent global challenges in decarbonisation and carbon capture.
Climate change is not just a scientific challenge, it is not just a business innovation challenge, it is also a people challenge. We have found that remarkable things happen when you bring together some of the world’s most talented people who are all highly motivated by the mission to fight the climate emergency. True's investment is therefore a valuable recognition of our people-first approach.
I'm also delighted that Carbon13 is joining True's community of decarbonisation startups. Launching and scaling ventures with credible claims to significant emissions mitigation was a foundational principle when I was developing Carbon13 with my cofounders. Again, it is our people-first approach which drives this, as our programmes inculcate carbon intelligence within the founding team to empower them to make strategic decisions based as much on carbon reduction as on commercial value. Ultimately, in the world of Net Zero 2050, there will be no distinction between the two.”
Also commenting, Priscilla Tyler, Vice President at True Ventures, said: “Our investment in Carbon13 and its focused support of carbon-neutralizing technology is an incredible complement to our portfolio of climate tech investments. What’s more, the Carbon13 team aligns deeply with our values and belief in the creative entrepreneur. They invest in people first and tech second. We’re thrilled for this partnership and to help embolden their important work around mitigating climate change.”
- ENDS -
About Carbon13
Carbon13 is the Venture Builder for the Climate Emergency. Since 2021, three programmes of the Venture Builder Europe, Venture Builder UK, and Venture Launchpad, have invested in 46 startups, and worked with over 350 founders. Carbon13 grew out of the Cambridge ecosystem of technology, academia and innovation, and has expanded to Berlin, our new base in the EU. Notable Carbon13 alumni include Kita, Infyos, Nium, Biozeroc, Materials Nexus and Tierra Foods. Kita and Tierra Foods are both nominated for Earthshot 2023 prizes.
Carbon13 media pack available here: https://carbonthirteen.com/media/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230719330116/en/
Contact information
PR and enquiries
contact
Dark Green PR
Tel: +44 (0)7940 968704
team@darkgreenpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
One in Three Western Consumers Now Buy Products Discovered on Social Platforms as AI Reshapes Commerce, According to NIQ26.6.2026 11:00:00 EEST | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, today revealed new analysis presented at The Consumer Goods Forum (CGF) Global Summit showing that nearly one in three consumers in Western markets now purchase products they first discover on social platforms, as artificial intelligence (AI) and emerging commerce models accelerate a shift toward discovery-led commerce. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626970024/en/ Presented by Emilie Darolles, President, West Europe, NIQ, the findings highlight a fundamental shift in how consumers discover, evaluate, and purchase products—blurring traditional geographic, channel, and operational boundaries. New growth engine: commerce models scaling from East to West NIQ’s latest global insights show that live, social, and quick commerce models—long scaled across Asia—are now a significant driver of incremental digital growth globally, as these formats expand rapidl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom